FDA approves 1st new pediatric ADHD drug in more than a decade,

In clinical trials, 477 children ages 6 to 11 took Qelbree for six weeks, and symptoms of inattention and hyperactivity were found to decrease by 50 …, In clinical trials, 477 children ages 6 to 11 took Qelbree for six weeks, and symptoms of inattention and hyperactivity were found to decrease by 50 …, Read More

Scroll to Top